The FDA lists GLP-1 medications as no longer in shortage in 2026, yet patients still call multiple pharmacies trying to find their dose. There’s a gap between regulatory definitions and ground-level supply. This piece explains the actual supply chain choke points that keep specific strengths of these drugs hard to find.<\/p>\n
At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.<\/p>\n
Semaglutide is a 31-amino-acid synthetic peptide.<\/strong> Tirzepatide is 39 amino acids. Both are produced through solid-phase peptide synthesis, a chemistry process invented in the 1960s by Bruce Merrifield and refined steadily since. The technique attaches amino acids one at a time to a solid resin support, then cleaves the finished peptide off.<\/p>\n Quick Answer: GLP-1 drugs are 30-39 amino acid peptides that require complex multi-step solid-phase synthesis<\/p>\n Each amino acid coupling step has to be near-quantitative because impurities and incomplete sequences accumulate quickly across 30+ steps. A single low-yield step in the chain compounds across all subsequent steps. Getting the overall yield high enough to be commercial requires expensive coupling reagents, careful temperature control, and extensive in-process purification.<\/p>\n Then comes the purification of the crude peptide. Reverse-phase HPLC at industrial scale runs slowly and requires huge solvent volumes. Final isolation, freeze-drying, and stability testing add weeks of cycle time.<\/p>\n The whole process from raw amino acids to vialed drug substance takes roughly 6 to 9 months end to end at commercial scale.<\/p>\n Globally, fewer than a dozen facilities have the scale and certification to produce semaglutide and tirzepatide drug substance.<\/strong> Novo Nordisk’s Kalundborg, Denmark facility is the largest. The company also expanded production in Bagsvaerd, Denmark and acquired three Catalent sites in 2024 to add capacity.<\/p>\n Eli Lilly’s Lebanon, Indiana plant came online in late 2025 for injectable tirzepatide. Lilly also produces in Indianapolis and operates fill-finish at Concord, North Carolina. Mount Vernon, Indiana is in pre-commercial validation for 2027.<\/p>\n Contract manufacturers like Bachem, Polypeptide Group, and CordenPharma supply some of the global peptide capacity for various brands. The number of qualified GMP peptide manufacturers is small enough that capacity expansion takes years, not months.<\/p>\n This is why “just make more” isn’t a quick fix.<\/p>\n Drug substance is the active ingredient.<\/strong> Drug product is the substance formulated into a dose, packaged, and labeled. The step in between is fill-finish: putting sterile drug formulation into vials, cartridges, or autoinjectors.<\/p>\n For injectable peptides, fill-finish requires sterile aseptic processing in cleanrooms. Pen and autoinjector devices require complex multi-component assembly. Vials are simpler than pens but still require sterile filling.<\/p>\n In 2026, autoinjector assembly is the actual bottleneck for both Wegovy\u00ae and Zepbound\u00ae. Drug substance is no longer the limiting step. Pen components come from a small number of global suppliers, including SHL Medical and Owen Mumford, and Lilly is in-sourcing more of that supply chain.<\/p>\n Vials are easier to scale than pens, which is why LillyDirect Self-Pay vials ship more reliably than retail pen prescriptions.<\/p>\n Roughly 5-fold from 2022 to 2026 in the U.S.<\/strong> alone. Novo Nordisk reported U.S. dispensing of semaglutide injection at about 800,000 pens per month in mid-2022. By Q1 2026, that figure was approximately 4.5 million per month.<\/p>\n Eli Lilly went from negligible tirzepatide volume in 2022 (Mounjaro\u00ae launched in May 2022) to roughly 4.2 million pen-equivalents per month in early 2026. The combined two-molecule U.S. market is approaching 9 million doses per month.<\/p>\n Demand drivers include the original obesity and diabetes indications, plus successive label expansions:<\/p>\n Each indication expands the eligible population by millions.<\/p>\n They are. The pace is what it is. A new sterile peptide manufacturing facility costs $1 to $3 billion and takes 4 to 7 years from notable to FDA-approved commercial production. The bottleneck is qualified workforce, specialized equipment, and FDA inspection cycles, not capital.<\/p>\n Lilly’s $25 billion buildout includes the Lebanon, Indiana site (announced 2020, first commercial production 2025) and Mount Vernon, Indiana (announced 2024, targeting 2027 first output). Novo’s Catalent acquisition added three existing facilities in 2024, the fastest route to new capacity because the buildings were already validated.<\/p>\n Both companies have publicly forecast that 2026 will see continued tight supply at higher doses, with normalization through Q4 2026 and 2027 assuming no new mega-indication approvals.<\/p>\n Maintenance doses (Wegovy 2.4 mg, Zepbound 12.5-15 mg, Ozempic\u00ae 1-2 mg) are tighter than starter doses because of where most patients sit on the dosing curve.<\/strong><\/p>\n Manufacturers prioritize starter strengths to keep new patient titration flowing. Cutting off new patient starts creates worse PR than uneven maintenance supply, and the long-term revenue calculation favors keeping the onboarding funnel open.<\/p>\n Maintenance doses are also where the largest prescription volumes concentrate. A patient on 2.4 mg Wegovy will dispense that dose every month for years. The cumulative demand outpaces what manufacturers projected during 2023 to 2024 capacity planning.<\/p>\n The 1.7 mg Wegovy pen specifically is hit by two factors: many patients stay on it as a maintenance dose rather than escalating to 2.4 mg due to tolerability or cost, and it shares fill-finish lines with other strengths.<\/p>\n Key Takeaway: Autoinjector device manufacturing is the actual bottleneck in 2026, not the drug substance<\/p>\n A big one. Insurance coverage expansion drives demand independent of clinical indication. When Medicare began covering Wegovy for cardiovascular indication patients in 2024, that opened the program to tens of millions of new eligible patients overnight.<\/p>\n Commercial insurance coverage of obesity GLP-1 therapy expanded steadily from 2022 to 2026. Major employer plans now commonly cover Wegovy and Zepbound for patients meeting BMI and clinical criteria. State Medicaid programs vary, with about half covering obesity GLP-1 therapy in 2026.<\/p>\n When insurance covers, prescriptions get written. When insurance doesn’t, demand exists but is suppressed by cost. The 2026 environment has more insurance coverage than ever, which fuels demand.<\/p>\n Less so than in 2022 to 2024.<\/strong> During the shortage period, prescribers wrote a lot of off-label Ozempic for weight loss because Wegovy was unobtainable. As Wegovy supply recovered, off-label prescribing pulled back. Pharmacists and prescribers route weight-management patients to Wegovy now.<\/p>\n Off-label use of Mounjaro for obesity is uncommon because Zepbound is the labeled brand for that indication. Insurance generally won’t cover off-label use, which is a strong disincentive.<\/p>\n A separate question is cosmetic off-label use in patients with BMI under the labeled obesity threshold (BMI 27 with comorbidity, or BMI 30 without). That practice continues at meaningful volume in 2026, especially in cash-pay direct-to-consumer telehealth, and contributes to demand pressure.<\/p>\n Compounded semaglutide and tirzepatide supply contributed substantially during the 2022 to 2024 shortage period.<\/strong> Once the FDA declared the shortages resolved, 503B outsourcing facility production of brand-equivalent compounds ended.<\/p>\n In 2026, compounded GLP-1 is available through state-licensed 503A pharmacies on a patient-specific basis when there’s documented clinical justification. The total volume is much smaller than during the shortage period.<\/p>\n Compounded supply doesn’t directly compete with brand supply for drug substance, because most compounders source API from FDA-registered suppliers that aren’t part of the Novo or Lilly supply chains. So compounded supply doesn’t worsen brand shortages, despite occasional rhetoric to the contrary.<\/p>\n Manufacturer guidance points to continued tight maintenance-dose supply through Q3 2026, with normalization in Q4 2026 and 2027.<\/strong> Both Novo and Lilly are bringing additional fill-finish capacity online through 2026.<\/p>\n New indication approvals could disrupt that trajectory. The FLOW chronic kidney disease indication for semaglutide is expected to expand the eligible population by millions. SYNERGY-NASH and ESSENCE trials for tirzepatide and semaglutide in liver disease could add more.<\/p>\n Patients should expect uneven retail supply through 2026 with steadier supply through mail-order and direct-to-consumer channels. Manufacturer capacity is growing faster than demand for the first time since 2022, but the gap is still closing.<\/p>\n Bottom line: SELECT, FLOW, SURMOUNT-OSA, and other indication approvals keep widening the eligible patient pool<\/p>\n Semaglutide and tirzepatide are patent-protected for years. The earliest semaglutide generics are expected in the early 2030s. No FDA-approved generic exists in 2026.<\/p>\n GLP-1 agonists are synthetic peptides, not biologics in the regulatory sense. Biosimilar pathways don’t apply. Generic peptide drugs go through standard ANDA filings.<\/p>\n Several are in development. Eli Lilly’s retatrutide (triple agonist) and Novo Nordisk’s CagriSema (cagrilintide-semaglutide) are in late-stage trials. Approvals would expand options but not before 2026 to 2027.<\/p>\n Brand differentiation by indication and dose. Same molecule, different label and trial program. Ozempic for diabetes, Wegovy for obesity. Mounjaro for diabetes, Zepbound for obesity.<\/p>\n TrimRx provides personalized compounded semaglutide and tirzepatide through licensed pharmacies when the clinical case applies. We aren’t a substitute for brand product.<\/p>\n Possibly. Medicare price negotiation for semaglutide takes effect in 2027. Commercial pricing tracks PBM contract negotiations. More capacity gives payers more use.<\/p>\n Faster than usual, yes. The combination of high effectiveness, broad indications, and chronic dosing made GLP-1 demand grow faster than capacity planning anticipated.<\/p>\n Disclaimer:<\/strong> This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.<\/p>\n","protected":false},"excerpt":{"rendered":" The FDA lists GLP-1 medications as no longer in shortage in 2026, yet patients still call multiple pharmacies trying to find their dose.<\/p>\n","protected":false},"author":11,"featured_media":91040,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_yoast_wpseo_title":"Why GLP-1 Medications Keep Running Out: Supply Chain Explained","_yoast_wpseo_metadesc":"The FDA lists GLP-1 medications as no longer in shortage in 2026, yet patients still call multiple pharmacies trying to find their dose.","_yoast_wpseo_focuskw":"why glp 1","footnotes":"","_flyrank_wpseo_metadesc":""},"categories":[6],"tags":[],"class_list":["post-91041","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-glp-1"],"_links":{"self":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/91041","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/comments?post=91041"}],"version-history":[{"count":1,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/91041\/revisions"}],"predecessor-version":[{"id":92072,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/91041\/revisions\/92072"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media\/91040"}],"wp:attachment":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media?parent=91041"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/categories?post=91041"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/tags?post=91041"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}How Many Factories Actually Make These Drugs?<\/h2>\n
What Is Fill-finish and Why Does It Matter?<\/h2>\n
How Has Demand Grown?<\/h2>\n
\n
Why Don’t They Just Build More Factories?<\/h2>\n
Why Are Some Doses Tighter Than Others?<\/h2>\n
What Role Does Insurance Play?<\/h2>\n
Is the Off-label Market Still Significant?<\/h2>\n
What About Compounded Versions?<\/h2>\n
What Does the Next Year Look Like?<\/h2>\n
FAQ<\/h2>\n
Why Don’t Generic Versions Help?<\/h3>\n
What About Biosimilars?<\/h3>\n
Could a Competitor Drug Help?<\/h3>\n
Why Is the Same Drug Sold Under Two Names?<\/h3>\n
Does TrimRx Help with Brand Supply Gaps?<\/h3>\n
Will Prices Come Down with More Capacity?<\/h3>\n
Is This Normal for a New Drug Class?<\/h3>\n